1 / 15

Prasugrel vs. Clopidogrel in ACS: A Negative Trial in Ischemic Outcomes

This TRILOGY study found no significant difference in ischemic outcomes despite greater P2Y12 receptor inhibition with prasugrel than with clopidogrel. Explore the challenges, exclusion criteria, and implications for novel anticoagulant trials and patient-centered outcomes research. Funding cuts and cluster randomization are impacting today's trial design in the NIH Health Care Systems Research Collaboratory. Learn more at the Framingham Heart Study references.

wesley-wallace
Télécharger la présentation

Prasugrel vs. Clopidogrel in ACS: A Negative Trial in Ischemic Outcomes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Negative Trials

  2. TRILOGY ACSNo significant difference in ischemic outcomes despite greater P2Y12 receptor inhibition with prasugrel than with clopidogrel

  3. ISIS-2, GUSTO: Exclusion Criteria

  4. Today’s Trial Design Challenges

  5. NIH Health Care Systems Research Collaboratory

  6. Cluster Randomization

  7. Framingham Heart Study Funding Cut by 40 Percent

  8. Novel Anticoagulant Trials

  9. Patient-Centered Outcomes Research

  10. Abbreviations

  11. Abbreviations (cont)

  12. References

  13. References (cont)

  14. References (cont)

More Related